Innovative Scientific Solutions competitors

Bernhard Montag is a CEO:Healthcare Business at Siemens. He has worked as Head:Marketing at Siemens, Consultant at Siemens, and Mgr:Export Sales at Siemens. Bernd attended Friedrich-Alexander-Universitaet Erlangen-Nuernberg.

Andre Lacroix is a Chairman at Intertek, Chief Executive Officer at Intertek, and Chairman at Good Restaurants AG. He has experience at PEPSICO INC and has worked as Chief Executive Officer at INCHCAPE PLC, Chairman at Euro Disney S.C.A., and Board Member at Intertek. Andre works or has worked at Ernst & Young LLP and COLGATE PALMOLIVE CO. He studied at Rouen Business School.

Mr.. Duncan is an experienced financial and biotech executive who has served for the past 30 years as a CEO in the biotech industry. He was founding Chairman of CRX Medical, Inc., which developed the first wound closure products manufactured by Closure Medical (Nasdaq:CLSR, acquired by Johnson & Johnson). Mr. Duncan became CEO of Sphinx Pharmaceuticals Corporation and led the company through three rounds of venture funding, an IPO, and an acquisition by Eli Lilly. Prior to its sale to Lilly, Sphinx moved compounds from early discovery through Phase 2 clinical trials in oncology and dermatology. In 1995 Mr. Duncan became CEO of Incara Pharmaceuticals Corporation, which he took public in 1996. Under Mr. Duncan’s leadership, Incara conducted Phase 2 and 3 clinical trials for compounds intended to treat gastrointestinal and cardiovascular diseases and advanced a cell therapy program from start-up through an IND filing. Beginning in 2006, Mr. Duncan was Chairman and CEO of Ercole Biotech, Inc., an RNA therapeutics company focused on directing alternative splicing to create therapeutic proteins for the treatment of Duchenne muscular dystrophy and other therapeutic targets. Ercole was acquired by Sarepta Therapeutics (SRPT) in 2008. Sarepta later received approval for the treatment of muscular dystrophy using the company’s technology. In 2009, Mr. Duncan supervised a drug discovery team focused on screening, medicinal chemistry and animal studies for novel potentiators of existing antibiotics for gram-negative infections. Beginning in late 2009, he was CEO of Otologic Pharmaceutics, Inc. where he directed the conduct of IND enabling safety studies and Phase 1 clinical trials in the field of hearing loss. In 2018 Mr. Duncan became CEO of Valanbio Therapeutics, Inc.

Richard Geiger is a product design engineer with over 20 years of design experience in Aerospace, Medical, and Consumer Products. Mr. Geiger has been responsible for all facets of product development from conceptualization, design, testing, manufacturing, and service. He has experience designing products utilizing a wide variety of manufacturing processes: rapid prototyping, machining, metal casting, stamping, injection molding, metal and plastic extrusion, long and short fiber composites. Mr. Geiger has authored over 20 US Patents and is currently pursuing a Ph.D. in Electrical Engineering at Penn State University in Power Electronics.

Larry Jordan, Chief Executive Officer and co-founder of Wi-Tronix, is committed to a global vision of saving lives by improving the safety, service reliability, and operational efficiency of transportation systems for the rail industry. An inventor and innovator, Larry holds multiple patents in the area of locomotive control systems. He believes passionately that innovation can provide the future of rail safety. Today, Larry leads the Wi-Tronix team in providing remote monitoring, video analytics and predictive diagnostic solutions to railways, ensuring the most efficient and reliable movement of goods and people throughout the world.